{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:00:53Z","timestamp":1788188453128,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The clinical significance of abnormally high levels of carbohydrate antigen (CA) 19-9 after resection of biliary tract cancer (BTC) is not well established. The aim of this study was to determine the prognostic value of CA19-9 normalization in patients undergoing resection of BTC with curative intent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with BTC undergoing resection with curative intent (1996\u20132015) were divided into those with normal preoperative CA19-9 level (normal CA19-9 group), those with an abnormally high preoperative CA19-9 level (over 37 units\/ml) and normal postoperative CA19-9 level (normalization group), and those with an abnormally high preoperative CA19-9 level and abnormally high postoperative CA19-9 level (non-normalization group). Overall survival (OS) was analysed and predictors of OS were determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The normal CA19-9 group (180 patients) and normalization group (74) had better OS than the non-normalization group (58) (3-year OS rate 70\u00b74, 73 and 31 per cent respectively; both P &amp;lt; 0\u00b7001). The normal CA19-9 and normalization groups had equivalent OS (P = 0\u00b7880). On multivariable analysis, factors associated with worse OS were lymph node metastases (hazard ratio (HR) 1\u00b778; P = 0\u00b7014) and abnormally high postoperative CA19-9 level (HR 3\u00b716; P &amp;lt; 0\u00b7001). In the normalization group, OS did not differ after R0versus R1 resection (3-year OS rate 69 versus 62 per cent respectively; P = 0\u00b7372); in the non-normalization group, patients with R1 resection had worse OS (3-year OS rate 36 and 20 per cent for R0 and R1 respectively; P = 0\u00b7032).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Non-normalization of CA19-9 level after resection of BTC with curative intent was associated with worse OS. R1 resection was associated with a particularly poor prognosis when CA19-9 levels did not normalize.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.10415","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T11:32:40Z","timestamp":1483529560000},"page":"267-277","source":"Crossref","is-referenced-by-count":46,"title":["Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer"],"prefix":"10.1093","volume":"104","author":[{"given":"S","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Passot","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T A","family":"Aloia","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y S","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-N","family":"Vauthey","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,4]]},"reference":[{"key":"2021020617353598600_bjs10415-bib-0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"2021020617353598600_bjs10415-bib-0002","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","article-title":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","volume":"29","author":"Wang","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021020617353598600_bjs10415-bib-0003","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jjco\/hyt038","article-title":"An updated report of the trends in cancer incidence and mortality in Japan","volume":"43","author":"Katanoda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2021020617353598600_bjs10415-bib-0004","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021020617353598600_bjs10415-bib-0005","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021020617353598600_bjs10415-bib-0006","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/cncr.20906","article-title":"Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma","volume":"103","author":"Wakai","year":"2005","journal-title":"Cancer"},{"key":"2021020617353598600_bjs10415-bib-0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3857\/roj.2014.32.2.63","article-title":"Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy","volume":"32","author":"Koo","year":"2014","journal-title":"Radiat Oncol J"},{"key":"2021020617353598600_bjs10415-bib-0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3857\/roj.2014.32.1.7","article-title":"Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer","volume":"32","author":"Im","year":"2014","journal-title":"Radiat Oncol J"},{"key":"2021020617353598600_bjs10415-bib-0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/clinchem\/29.3.549","article-title":"Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9","volume":"29","author":"Del Villano","year":"1983","journal-title":"Clin Chem"},{"key":"2021020617353598600_bjs10415-bib-0010","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/jso.23666","article-title":"Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma","volume":"110","author":"Kondo","year":"2014","journal-title":"J Surg Oncol"},{"key":"2021020617353598600_bjs10415-bib-0011","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1245\/s10434-010-1529-7","article-title":"Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer","volume":"18","author":"Chung","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2021020617353598600_bjs10415-bib-0012","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2005.05.3934","article-title":"Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma","volume":"24","author":"Ferrone","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021020617353598600_bjs10415-bib-0013","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1200\/JCO.2008.18.6288","article-title":"Postresection CA19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704","volume":"26","author":"Berger","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021020617353598600_bjs10415-bib-0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00000658-199207000-00008","article-title":"Prognostic value of CA 19.9 levels in colorectal cancer","volume":"216","author":"Filella","year":"1992","journal-title":"Ann Surg"},{"key":"2021020617353598600_bjs10415-bib-0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0002-9610(00)00549-3","article-title":"Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer","volume":"181","author":"Marrelli","year":"2001","journal-title":"Am J Surg"},{"key":"2021020617353598600_bjs10415-bib-0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/172460089901400207","article-title":"Disappearance curves for tumor markers after resection of intrathoracic malignancies","volume":"14","author":"Yoshimasu","year":"1999","journal-title":"Int J Biol Markers"},{"key":"2021020617353598600_bjs10415-bib-0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00534-012-0561-3","article-title":"TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos)","volume":"20","author":"Kiriyama","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2021020617353598600_bjs10415-bib-0018","first-page":"350","article-title":"The clinical utility of the CA 19-9 tumor-associated antigen","volume":"85","author":"Steinberg","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"2021020617353598600_bjs10415-bib-0019","first-page":"5501","article-title":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer","volume":"47","author":"Tempero","year":"1987","journal-title":"Cancer Res"},{"key":"2021020617353598600_bjs10415-bib-0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11605-013-2369-0","article-title":"Safety and efficacy of portal vein embolization before planned major or extended hepatectomy: an institutional experience of 358 patients","volume":"18","author":"Shindoh","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"2021020617353598600_bjs10415-bib-0021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jamcollsurg.2016.01.060","article-title":"Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma","volume":"223","author":"Ribero","year":"2016","journal-title":"J Am Coll Surg"},{"key":"2021020617353598600_bjs10415-bib-0022","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000000728","article-title":"Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study","volume":"261","author":"Shindoh","year":"2015","journal-title":"Ann Surg"},{"key":"2021020617353598600_bjs10415-bib-0023","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2021020617353598600_bjs10415-bib-0024","volume-title":"TNM Classification of Malignant Tumors","author":"International Union Against Cancer (UICC)","year":"2009","edition":"7th"},{"key":"2021020617353598600_bjs10415-bib-0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jjco\/hyu210","article-title":"Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC)","volume":"45","author":"Ji","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2021020617353598600_bjs10415-bib-0026","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.pan.2014.09.006","article-title":"Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis","volume":"14","author":"Yamamoto","year":"2014","journal-title":"Pancreatology"},{"key":"2021020617353598600_bjs10415-bib-0027","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11605-012-1859-9","article-title":"Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma","volume":"16","author":"Sugiura","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"2021020617353598600_bjs10415-bib-0028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/archsurg.138.9.951","article-title":"Utility of tumor markers in determining resectability of pancreatic cancer","volume":"138","author":"Schlieman","year":"2003","journal-title":"Arch Surg"},{"key":"2021020617353598600_bjs10415-bib-0029","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/bjs.9752","article-title":"Prognostic impact of lymph node metastasis in distal cholangiocarcinoma","volume":"102","author":"Kiriyama","year":"2015","journal-title":"Br J Surg"},{"key":"2021020617353598600_bjs10415-bib-0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1245\/s10434-014-4044-4","article-title":"Lymph node metastases in patients undergoing surgery for a gallbladder cancer. Extension of the lymph node dissection and prognostic value of the lymph node ratio","volume":"22","author":"Birnbaum","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.10415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/104\/3\/267\/36207930\/bjs10415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/104\/3\/267\/36207930\/bjs10415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T14:17:34Z","timestamp":1621520254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/104\/3\/267-277\/6094908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,4]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,1,4]]},"published-print":{"date-parts":[[2017,2,3]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.10415","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2]]},"published":{"date-parts":[[2017,1,4]]}}}